OXALIPLATINE HOSPIRA 5 mg/ml
Sponsors
Centre Hospitalier Universitaire De Dijon, Fondation Franc.Cancerologie Digestive
Conditions
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARYMICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND
A HIGH IMMUNE INFILTRATEmicrosatellite stable (MSS) colorectal cancer with liver-dominant metastasis
Phase 2
FFCD - 1703 - POCHI : PEMBROLIZUMAB in combination with XELOX or FOLFOX-BEVACIZUMAB in patients with Microsatellite Stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof-of-concept study. Phase II – non-randomised- multicentre.
Not yet recruitingCTIS2024-515788-73-00
Target: 55Updated: 2025-10-28
A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OR SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB ( IMMUNE CHECKPOINT INHIBITOR) IN PATIENTS WITH LIVER-DOMINANT METASTATIC COLORECTAL CANCER
Not yet recruitingCTIS2024-517204-11-00
Target: 52Updated: 2024-08-30
PRODIGE 69 – FOLFIRINEC -
FOLFIRINOX versus PLATINUM - ETOPOSIDE as first line chemotherapy for metastatic grade 3 poorly differentiated neuroendocrine carcinoma of gastro entero pancreatic and unknown primary associated with molecular profiling for therapeutic targets & predictive biomarkers identification
Not yet recruitingCTIS2024-515300-39-00
Target: 218Updated: 2025-09-23